FDA Issues Priority Vouchers to Three Companies for Psychedelic Medication Reviews
The Food and Drug Administration announced on April 24, 2026, that it is issuing national priority vouchers to three companies to fast-track reviews of psychedelic medications. The companies are studying psilocybin for depression and methylone for PTSD. The move follows President Trump's executive order to expedite such research.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)The Food and Drug Administration announced on April 24, 2026, that it is issuing national priority vouchers to three companies to help fast-track the review of certain psychedelic medications. The vouchers aim to accelerate the evaluation of psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone for post-traumatic stress disorder, @ABC reported.
FDA Commissioner Dr.
' The agency also announced it is allowing an early phase clinical study of noribogaine hydrochloride to move forward following an Investigational New Drug submission. Noribogaine hydrochloride is the principal psychoactive substance of the drug ibogaine.
The announcements follow President Donald Trump's executive order, signed over the weekend prior to April 24, 2026, directing the FDA to expedite its review of certain psychedelics.
The order seeks to accelerate research and approval of psychedelic-based therapies to treat mental health conditions including PTSD, depression and addiction. Psilocybin mushrooms were photographed standing ready for harvest in a humidified fruiting chamber in the basement of a private home on July 28, 2023, in Fairfield County, Connecticut.
Key Facts
Story Timeline
3 events- 2026-04-24
FDA announces national priority vouchers to three companies for psychedelic medications and allows noribogaine hydrochloride study to proceed.
1 source@ABC - Weekend prior to 2026-04-24
President Donald Trump signs executive order directing FDA to expedite review of certain psychedelics.
1 source@ABC - 2023-07-28
Psilocybin mushrooms photographed ready for harvest in a humidified fruiting chamber in Fairfield County, Connecticut.
1 source@ABC
Potential Impact
- 01
Faster approval process for psychedelic treatments could increase availability for mental health conditions like depression and PTSD.
- 02
Potential benefits for veterans and others suffering from substance abuse and mental health issues through expedited therapies.
- 03
Advancement in clinical studies of substances like noribogaine may lead to new treatments for addiction.
Transparency Panel
Related Stories
indiatoday.intoday.inTrump Pauses Project Freedom in Strait of Hormuz Amid Progress on Iran Agreement
President Trump announced a temporary pause to Project Freedom, the U.S. effort to escort ships through the Strait of Hormuz, citing mutual agreement with Iran to facilitate finalizing a deal while the blockade remains in place. The decision follows requests from Pakistan and oth…
South Australian Railways photographer / Wikimedia (Public domain)Australian Government Introduces Levy on Tech Platforms to Support Local News Publishers
Australia's government introduced the News Bargaining Incentive to shield publishers from big tech's use of news content. President Trump imposed a 100% tariff on imported pharmaceuticals, but Australia stated it would not raise drug prices. On International Day of the Midwife, g…
inquisitr.comTom Homan Discusses Minneapolis Immigration Enforcement After Shooting
Tom Homan, White House Border Czar, stated that mass deportations can proceed in a smarter way. He acknowledged imperfections in the Minneapolis immigration crackdown following a deadly shooting. Homan highlighted efforts to address and fix issues after President Trump sent him t…